JUVAF (Juva Life) Accounts Payable: $3.00 Mil (As of Mar. 2023)


What is Juva Life Accounts Payable?

Juva Life JUVAF -90.00% Accounts Payable is $3.00 Mil as of Mar. 2023.

Juva Life's Accounts Payable for the quarter that ended in Mar. 2023 was $3.00 Mil.

Juva Life's quarterly Accounts Payable declined from Jun. 2022 ($1.92 Mil) to Sep. 2022 ($1.66 Mil) but then increased from Sep. 2022 ($1.66 Mil) to Mar. 2023 ($3.00 Mil).

Juva Life's annual Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2019 ($0.52 Mil) and increased from Dec. 2019 ($0.52 Mil) to Dec. 2020 ($1.88 Mil).

Juva Life Accounts Payable Historical Data

* Premium members only.

The historical data trend for Juva Life's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Juva Life Accounts Payable Chart

Juva Life Annual Data
Trend Dec19 Dec20
Accounts Payable
0.52 1.88

Juva Life Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Mar22 Jun22 Sep22 Mar23
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 2.46 1.92 1.66 3.00

Juva Life Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $3.00 Mil mean?
Juva Life (JUVAF) has a Accounts Payable of $3.00 Mil as of Mar. 2023. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Juva Life and its competitors.
Is Juva Life's Accounts Payable too high?
Juva Life's current Accounts Payable is $3.00 Mil.
How does Juva Life's Accounts Payable compare to AVRW and UPC?
Juva Life's Accounts Payable of $3.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Juva Life and its competitors. Juva Life's current Accounts Payable is $3.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Juva Life stock overvalued right now?
Juva Life (JUVAF) has a current Accounts Payable of $3.00 Mil. The current Accounts Payable is $3.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Juva Life (JUVAF), the current Accounts Payable is $3.00 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Juva Life Business Description

Address 885 West Georgia Street, Suite 1400, Vancouver, BC, CAN, V6C 3E8
Juva Life Inc is a life science company with both pharmaceutical research and development and consumer facing operations in cannabis production and distribution.